{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:51Z","timestamp":1792440591643,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10528-023-10580-w","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T10:02:01Z","timestamp":1701511321000},"page":"2907-2932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Frequency of CYP2D6 and CYP3A4\/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-6838","authenticated-orcid":false,"given":"Sireen Abdul Rahim","family":"Shilbayeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman Sharaf","family":"Adeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Shawqi","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah Fathy","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawwaz Abdul Razaq","family":"Al Enazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezzeldeen Hasan","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel Mohammed","family":"Binduraihem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"10580_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.etap.2013.09.008","volume":"36","author":"MS Al-Dosari","year":"2013","unstructured":"Al-Dosari MS, Al-Jenoobi FI, Alkharfy KM, Alghamdi AM, Bagulb KM, Parvez MK, Al-Mohizea AM, Al-Muhsen S, Halwani R (2013) High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians. Environ Toxicol Pharmacol 36:1063\u20131067. https:\/\/doi.org\/10.1016\/j.etap.2013.09.008","journal-title":"Environ Toxicol Pharmacol"},{"key":"10580_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/ijerph16040658","volume":"16","author":"NB Almandil","year":"2019","unstructured":"Almandil NB, Alkuroud DN, AbdulAzeez S, AlSulaiman A, Elaissari A, Borgio JF (2019) Environmental and genetic factors in autism spectrum disorders: special emphasis on data from Arabian studies. Int J Environ Res Public Health 16:658. https:\/\/doi.org\/10.3390\/ijerph16040658","journal-title":"Int J Environ Res Public Health"},{"key":"10580_CR3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Publication","year":"2013","unstructured":"American Psychiatric Publication (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Publication, Washington, DC"},{"key":"10580_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/1096-9888(200006)35:6<718::AID-JMS999>3.0.CO;2-O","volume":"35","author":"M Aravagiri","year":"2000","unstructured":"Aravagiri M, Marder SR (2000) Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography\/electrospray tandem mass spectrometry. J Mass Spectrom 35:718\u2013724.","journal-title":"J Mass Spectrom"},{"key":"10580_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","volume":"29","author":"L Bertilsson","year":"1995","unstructured":"Bertilsson L (1995) Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192\u2013209.","journal-title":"Clin Pharmacokinet"},{"key":"10580_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4274\/tjcamh.galenos.2020.88597","volume":"27","author":"M Be\u015fenek","year":"2020","unstructured":"Be\u015fenek M (2020) What are the sociodemographic and clinical risk factors for autism spectrum disorder? Turk J Child Adolesc Ment Health 27:147\u2013155. https:\/\/doi.org\/10.4274\/tjcamh.galenos.2020.88597","journal-title":"Turk J Child Adolesc Ment Health"},{"key":"10580_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/phe.10.45","volume":"4","author":"K Blankenship","year":"2010","unstructured":"Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6\u201317 years. Ped Health 4:375\u2013381. https:\/\/doi.org\/10.2217\/phe.10.45","journal-title":"Ped Health"},{"key":"10580_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1461145798001187","volume":"1","author":"LD Bradford","year":"1998","unstructured":"Bradford LD, Kirlin WG (1998) Polymorphism of CYP2D6 in black populations: implications for psychopharmacology. Int J Neuropsychopharmacol 1:173\u2013185. https:\/\/doi.org\/10.1017\/S1461145798001187","journal-title":"Int J Neuropsychopharmacol"},{"key":"10580_CR9","first-page":"509","volume":"30","author":"C Bruckner","year":"2022","unstructured":"Bruckner C, Shah M, Black D, Marjanovic M (2022) Preemptive targeted pharmacogenomic testing with axiom pharmacofocus array. Eur J Hum Genet 30:509","journal-title":"Eur J Hum Genet"},{"key":"10580_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12272-018-1075-6","volume":"41","author":"JY Byeon","year":"2018","unstructured":"Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41:921\u2013930. https:\/\/doi.org\/10.1007\/s12272-018-1075-6","journal-title":"Arch Pharm Res"},{"key":"10580_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A (2020) Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin Transl Sci 13:116\u2013124. https:\/\/doi.org\/10.1111\/cts.12692","journal-title":"Clin Transl Sci"},{"key":"10580_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/humu.24243","volume":"42","author":"CS Chong","year":"2021","unstructured":"Chong CS, Limviphuvadh V, Maurer-Stroh S (2021) Global spectrum of population-specific common missense variation in cytochrome P450 pharmacogenes. Hum Mutat 42:1107\u20131123. https:\/\/doi.org\/10.1002\/humu.24243","journal-title":"Hum Mutat"},{"key":"10580_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1373\/49.4.542","volume":"49","author":"WH Chou","year":"2003","unstructured":"Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, De Leon J, Koch WH, Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542\u2013551. https:\/\/doi.org\/10.1373\/49.4.542","journal-title":"Clin Chem"},{"key":"10580_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-McLeod","year":"2015","unstructured":"Corena-McLeod M (2015) Comparative pharmacology of risperidone and paliperidone. Drugs R D 15:163\u2013174. https:\/\/doi.org\/10.1007\/s40268-015-0092-x","journal-title":"Drugs R D"},{"key":"10580_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13034-018-0243-2","volume":"12","author":"T Dodsworth","year":"2018","unstructured":"Dodsworth T, Kim DD, Procyshyn RM, Ross CJ, Honer WG, Barr AM (2018) A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health 12:37. https:\/\/doi.org\/10.1186\/s13034-018-0243-2","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10580_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cap.2015.0094","volume":"25","author":"A dos Santos Jr","year":"2015","unstructured":"Dos Santos Jr A, Henriques TB, De Mello MP, Neto APF, Paes LA, Della Torre OH, Sewaybricker LE, Fontana TS, Celeri EHRV, Junior GG, Dalgalarrondo P (2015) Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol 25:738\u2013748. https:\/\/doi.org\/10.1089\/cap.2015.0094","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10580_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/pl00005334","volume":"359","author":"J Fang","year":"1999","unstructured":"Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147\u2013151. https:\/\/doi.org\/10.1007\/pl00005334","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10580_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72:76\u201389. https:\/\/doi.org\/10.1067\/mcp.2002.125783","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","volume":"103","author":"A Gaedigk","year":"2018","unstructured":"Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, Committee PS (2018) The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther 103:399\u2013401. https:\/\/doi.org\/10.1002\/cpt.910","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"10580_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K et al (2015) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:127\u2013134. https:\/\/doi.org\/10.1002\/cpt.147","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR22","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41598-021-83570-w","volume":"11","author":"Y Hongkaew","year":"2021","unstructured":"Hongkaew Y, Gaedigk A, Wilffert B, Ngamsamut N, Kittitharaphan W, Limsila P, Sukasem C (2021) Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep 11:4158. https:\/\/doi.org\/10.1038\/s41598-021-83570-w","journal-title":"Sci Rep"},{"key":"10580_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"OD Howes","year":"2018","unstructured":"Howes OD, Rogdaki M, Findon JL et al (2018) Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British association for psychopharmacology. J Psychopharmacol 32:3\u201329. https:\/\/doi.org\/10.1177\/0269881117741766","journal-title":"J Psychopharmacol"},{"key":"10580_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cpt.1322","volume":"105","author":"R Huddart","year":"2019","unstructured":"Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, Bustamante CD, Altman RB, Klein TE (2019) Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. Clin Pharmacol Ther 105:1256\u20131262. https:\/\/doi.org\/10.1002\/cpt.1322","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbrc.2010.02.162","volume":"396","author":"M Ingelman-Sundberg","year":"2010","unstructured":"Ingelman-Sundberg M, Sim SC (2010) Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 396:90\u201394. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.162","journal-title":"Biochem Biophys Res Commun"},{"key":"10580_CR26","unstructured":"Janssen Pharmaceutica (2009) Risperidone [package insert]. July revision. Janssen Pharmaceutica, Titusville, NJ"},{"key":"10580_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/JCP.0b013e3181a289e0","volume":"29","author":"RH Kang","year":"2009","unstructured":"Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, Kim YK, Kim SH, Han C, Lee MS, Park JY (2009) Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 29:272\u2013277. https:\/\/doi.org\/10.1097\/JCP.0b013e3181a289e0","journal-title":"J Clin Psychopharmacol"},{"key":"10580_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bcp.14465","volume":"87","author":"SM Kloosterboer","year":"2021","unstructured":"Kloosterboer SM, De Winter BCM, Reichart CG et al (2021) Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol 87:1069\u20131081. https:\/\/doi.org\/10.1111\/bcp.14465","journal-title":"Br J Clin Pharmacol"},{"key":"10580_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/cap.2020.0093","volume":"31","author":"AA Maruf","year":"2021","unstructured":"Maruf AA, Stein K, Arnold PD, Aitchison KJ, Muller DJ, Bousman C (2021) CYP2D6 and antipsychotic treatment outcomes in children and youth: a systematic review. J Child Adolesc Psychopharmacol 31:33\u201345. https:\/\/doi.org\/10.1089\/cap.2020.0093","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10580_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00008571-199706000-00003","volume":"7","author":"RA McLellan","year":"1997","unstructured":"McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187\u2013191. https:\/\/doi.org\/10.1097\/00008571-199706000-00003","journal-title":"Pharmacogenetics"},{"key":"10580_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fphar.2016.00475","volume":"7","author":"S Medhasi","year":"2016","unstructured":"Medhasi S, Pinthong D, Pasomsub E, Vanwong N, Ngamsamut N, Puangpetch A, Chamnanphon M, Hongkaew Y, Pratoomwun J, Limsila P, Sukasem C (2016) Pharmacogenomic study reveals new variants of drug metabolizing enzyme and transporter genes associated with steady-state plasma concentrations of risperidone and 9-Hydroxyrisperidone in Thai autism spectrum disorder patients. Front Pharmacol 7:475. https:\/\/doi.org\/10.3389\/fphar.2016.00475","journal-title":"Front Pharmacol"},{"key":"10580_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162866","volume":"11","author":"C Mizzi","year":"2016","unstructured":"Mizzi C, Dalabira E, Kumuthini J et al (2016) A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS ONE 11:e0162866. https:\/\/doi.org\/10.1371\/journal.pone.0162866","journal-title":"PLoS ONE"},{"key":"10580_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/omi.2018.0114","volume":"22","author":"MG Naranjo","year":"2018","unstructured":"Naranjo MG, Rodrigues-Soares F, Penas-Lledo EM et al (2018) Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero- and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics. OMICS 22:575\u2013588. https:\/\/doi.org\/10.1089\/omi.2018.0114","journal-title":"OMICS"},{"key":"10580_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cpt.1643","volume":"107","author":"C Nofziger","year":"2020","unstructured":"Nofziger C, Turner AJ, Sangkuhl K et al (2020) PharmVar geneFocus: CYP2D6. Clin Pharmacol Ther 107:154\u2013170. https:\/\/doi.org\/10.1002\/cpt.1643","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bcpt.12803","volume":"121","author":"N Nuntamool","year":"2017","unstructured":"Nuntamool N, Ngamsamut N, Vanwong N, Puangpetch A, Chamnanphon M, Hongkaew Y, Limsila P, Suthisisang C, Wilffert B, Sukasem C (2017) Pharmacogenomics and efficacy of risperidone long-term treatment in Thai autistic children and adolescents. Basic Clin Pharmacol Toxicol 121:316\u2013324. https:\/\/doi.org\/10.1111\/bcpt.12803","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10580_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41390-019-0305-z","volume":"85","author":"KA Oshikoya","year":"2019","unstructured":"Oshikoya KA, Neely KM, Carroll RJ, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL (2019) CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res 85:602\u2013606. https:\/\/doi.org\/10.1038\/s41390-019-0305-z","journal-title":"Pediatr Res"},{"key":"10580_CR37","unstructured":"Otsuka Pharmaceutical Company Ltd (2009) Aripiprazole [package insert]. November revision. Otsuka Pharmaceutical Company Ltd, Tokyo, Japan"},{"key":"10580_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI32483","volume":"118","author":"DJ Posey","year":"2008","unstructured":"Posey DJ, Stigler KA, Erickson CA, McDougle CJ (2008) Antipsychotics in the treatment of autism. J Clin Invest 118:6\u201314. https:\/\/doi.org\/10.1172\/JCI32483","journal-title":"J Clin Invest"},{"key":"10580_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jmoldx.2019.04.003","volume":"21","author":"VM Pratt","year":"2019","unstructured":"Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE (2019) Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn 21:746\u2013755. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.04.003","journal-title":"J Mol Diagn"},{"key":"10580_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","volume":"18","author":"C Rafaniello","year":"2018","unstructured":"Rafaniello C, Sessa M, Bernardi FF et al (2018) The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 18:422\u2013430. https:\/\/doi.org\/10.1038\/tpj.2017.38","journal-title":"Pharmacogenomics J"},{"key":"10580_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/FPC.0b013e3283647c33","volume":"23","author":"Y Roke","year":"2013","unstructured":"Roke Y, Van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK (2013) The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet Genom 23:487\u2013493. https:\/\/doi.org\/10.1097\/FPC.0b013e3283647c33","journal-title":"Pharmacogenet Genom"},{"key":"10580_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13031","volume":"123","author":"M Saiz-Rodriguez","year":"2018","unstructured":"Saiz-Rodriguez M, Belmonte C, Roman M, Ochoa D, Jiang-Zheng C, Koller D, Mejia G, Zubiaur P, Wojnicz A, Abad-Santos F (2018) Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 123:474\u2013485. https:\/\/doi.org\/10.1111\/bcpt.13031","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10580_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.542342","volume":"12","author":"PF Salles","year":"2021","unstructured":"Salles PF, Perce-Da-Silva DS, Rossi AD, Raposo LR, Ramirez ADR, Bastos OMP, Pratt-Riccio LR, Cassiano GC, Baptista ARS, Cardoso CC, Banic DM, Machado RLD (2021) CYP2D6 allele frequency in five malaria vivax endemic areas from Brazilian Amazon region. Front Pharmacol 12:542342. https:\/\/doi.org\/10.3389\/fphar.2021.542342","journal-title":"Front Pharmacol"},{"key":"10580_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.05.007","volume":"190","author":"SR Sharma","year":"2018","unstructured":"Sharma SR, Gonda X, Tarazi FI (2018) Autism spectrum disorder: classification, diagnosis and therapy. Pharmacol Ther 190:91\u2013104. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.007","journal-title":"Pharmacol Ther"},{"key":"10580_CR45","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s10803-018-3521-1","volume":"48","author":"GN Soke","year":"2018","unstructured":"Soke GN, Maenner MJ, Christensen D, Kurzius-Spencer M, Schieve LA (2018) Prevalence of co-occurring medical and behavioral conditions\/symptoms among 4- and 8-year-old children with autism spectrum disorder in selected areas of the United States in 2010. J Autism Dev Disord 48:2663\u20132676. https:\/\/doi.org\/10.1007\/s10803-018-3521-1","journal-title":"J Autism Dev Disord"},{"key":"10580_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/JCP.0000000000000474","volume":"36","author":"C Sukasem","year":"2016","unstructured":"Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Chamkrachchangpada B, Sinrachatanant A, Limsila P (2016) Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol 36:141\u2013146. https:\/\/doi.org\/10.1097\/JCP.0000000000000474","journal-title":"J Clin Psychopharmacol"},{"key":"10580_CR47","unstructured":"Tayeb HT, Arafah MA, Bakheet D, Khalaf DM, Tarnoska A, Dzimiri N (2015) Prevalence of Cyp2d6 and its implications for personalized medicine in Saudi Arabs. In: ICHG 2015 (world academy of science, engineering and technology), London"},{"key":"10580_CR48","unstructured":"ThermoFisher Scientifuic Axiom pharmacofocus. https:\/\/www.thermofisher.com\/order\/catalog\/product\/952396. Accessed 3 July 2022"},{"key":"10580_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/pgs-2018-0167","volume":"20","author":"L Tilleman","year":"2019","unstructured":"Tilleman L, Weymaere J, Heindryckx B, Deforce D, Nieuwerburgh FV (2019) Contemporary pharmacogenetic assays in view of the PharmGKB database. Pharmacogenomics 20:261\u2013272. https:\/\/doi.org\/10.2217\/pgs-2018-0167","journal-title":"Pharmacogenomics"},{"key":"10580_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","volume":"27","author":"PW Troost","year":"2007","unstructured":"Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, Van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2007) Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 27:52\u201357. https:\/\/doi.org\/10.1097\/JCP.0b013e31802e68d5","journal-title":"J Clin Psychopharmacol"},{"key":"10580_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.dmpk.2016.01.005","volume":"31","author":"N Vanwong","year":"2016","unstructured":"Vanwong N, Ngamsamut N, Hongkaew Y, Nuntamool N, Puangpetch A, Chamnanphon M, Sinrachatanant A, Limsila P, Sukasem C (2016a) Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metab Pharmacokinet 31:156\u2013162. https:\/\/doi.org\/10.1016\/j.dmpk.2016.01.005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10580_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/cap.2014.0171","volume":"27","author":"N Vanwong","year":"2017","unstructured":"Vanwong N, Ngamsamut N, Medhasi S, Puangpetch A, Chamnanphon M, Tan-Kam T, Hongkaew Y, Limsila P, Sukasem C (2017) Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-Hydroxyrisperidone in Thai children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol 27:185\u2013191. https:\/\/doi.org\/10.1089\/cap.2014.0171","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10580_CR53","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/jcla.22009","volume":"30","author":"N Vanwong","year":"2016","unstructured":"Vanwong N, Prommas S, Puangpetch A, Hongkaew Y, Nuntamool N, Nakorn CN, Ngamsamut N, Limsila P, Sukasem C (2016b) Development and validation of liquid chromatography\/tandem mass spectrometry analysis for therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in pediatric patients with autism spectrum disorders. J Clin Lab Anal 30:1236\u20131246. https:\/\/doi.org\/10.1002\/jcla.22009","journal-title":"J Clin Lab Anal"},{"key":"10580_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.psychres.2018.02.055","volume":"279","author":"LM Walden","year":"2019","unstructured":"Walden LM, Brandl EJ, Tiwari AK, Cheema S, Freeman N, Braganza N, Kennedy JL, Muller DJ (2019) Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Res 279:111\u2013115. https:\/\/doi.org\/10.1016\/j.psychres.2018.02.055","journal-title":"Psychiatry Res"},{"key":"10580_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE (2021) An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 110:563\u2013572. https:\/\/doi.org\/10.1002\/cpt.2350","journal-title":"Clin Pharmacol Ther"},{"key":"10580_CR56","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0091270009347867","volume":"50","author":"Q Xiang","year":"2010","unstructured":"Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50:659\u2013666. https:\/\/doi.org\/10.1177\/0091270009347867","journal-title":"J Clin Pharmacol"},{"key":"10580_CR57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","volume":"57","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57:569\u2013575. https:\/\/doi.org\/10.1111\/j.1365-2125.2003.02061.x","journal-title":"Br J Clin Pharmacol"},{"key":"10580_CR58","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/dmcn.12470","volume":"56","author":"I Youngster","year":"2014","unstructured":"Youngster I, Zachor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, Soback S, Ziv-Baran T, Berkovitch M (2014) CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol 56:990\u2013994. https:\/\/doi.org\/10.1111\/dmcn.12470","journal-title":"Dev Med Child Neurol"},{"key":"10580_CR59","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3389\/fphar.2020.00596","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML (2020) The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol 11:596. https:\/\/doi.org\/10.3389\/fphar.2020.00596","journal-title":"Front Pharmacol"},{"key":"10580_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23\u201337. https:\/\/doi.org\/10.1007\/s00210-003-0832-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-023-10580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-023-10580-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-023-10580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T14:13:22Z","timestamp":1722348802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-023-10580-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10580"],"URL":"https:\/\/doi.org\/10.1007\/s10528-023-10580-w","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study was approved by both the Institutional Review Board (IRB) committee of Princess Nourah University (IRB Log Number: 20\u20130321) and KFMC (IRB Log Number: 20-758E).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from the parents or other legal guardians of the study participants after a clear rationalization of the study procedures was presented to them for review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}